Elan Win In IP Feud Over Skelaxin Confirmed By Judge

Law360, Los Angeles (November 1, 2013, 4:20 PM EDT) -- A Maryland federal judge on Thursday denied Classen Immunotherapies Inc.’s motion to reconsider or vacate a summary judgment granted to Irish pharmaceutical company Elan Pharmaceuticals Inc. in a stayed lawsuit over Elan’s alleged infringement of two patents related to a study of its muscle relaxant Skelaxin.

Classen, a corporation that developed and patented methods for identifying and commercializing new uses of existing drugs, sued Elan for patent infringement for studying the effect of food on the bioavailability of Skelaxin, using the study to identify a new...
To view the full article, register now.